T. Rowe Price Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

T. Rowe Price Associates’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,200	Closed	-$3.59M	–	3183
2025 Q1	$3.59M	Buy	+27,200	New	+$3.39M	﹤0.01%	1364

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's ITCI Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 115,424 shares — an estimated $15.2M sold.

T. Rowe Price Associates first reported a position in ITCI in Q1 2016 and held it in 37 quarters. The position peaked at $97.8M in Q2 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

T. Rowe Price Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 115,424 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $15.2M.
T. Rowe Price Associates first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 37 quarters.
T. Rowe Price Associates's Intra-Cellular Therapies Inc. position peaked at $97.8M in Q2 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.